ArmaGen, Inc.

Industry

  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
See more in Biomedtracker

Latest on ArmaGen, Inc.

In Vivo

JCR Pharma: Crossing Oceans And The Blood-Brain Barrier

 
• By Ben Comer

JCR Pharmaceuticals Co., Ltd. , headquartered in Ashiya, Hyōgo Prefecture, holds claim to several “firsts” in Japan. In 2010, the company launched Japan’s first biosimilar product (Epoetin alfa BS inj

Scrip

Pipeline Watch: Peficitinib, Ubrogepant, Apalutamide Phase III Read-Outs

 
• By John Davis

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Scrip

Shire's Wellhoefer On Genetic Disease R&D And Expanding Access To Medicines

 
• By Mandy Jackson

Shire PLC Vice President Hartmann Wellhoefer, Head of Genetic Diseases, Medical Affairs, recently spoke with Scrip about the company's research and development pipeline in lysosomal disorders and

Scrip

WORLD Symposium Notebook: New Data In Lysosomal Diseases And A Push For Earlier Testing

 
• By Mandy Jackson

The WORLD Symposium from Feb. 13 to 16 in San Diego brought together academic researchers and biopharmaceutical companies to share emerging research in lysosomal diseases, including next-generation en